Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline Review, H1 2017’, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

The report reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics and enlists all their major and minor projects

The report assesses Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ActiveSite Pharmaceuticals Inc

Adverum Biotechnologies Inc

Arrowhead Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Cevec Pharmaceuticals GmbH

CSL Ltd

Global Blood Therapeutics Inc

iBio Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Pharming Group NV

ProMetic Life Sciences Inc

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development

ActiveSite Pharmaceuticals Inc

Adverum Biotechnologies Inc

Arrowhead Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Cevec Pharmaceuticals GmbH

CSL Ltd

Global Blood Therapeutics Inc

iBio Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Pharming Group NV

ProMetic Life Sciences Inc

Shire Plc

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles

ADVM-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AROF-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATN-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATN-249 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCX-7353 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBT-18713 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icatibant acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-PKKLRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-PKKRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KVD-818 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanadelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones

Featured News & Press Releases

May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial

May 22, 2017: Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

May 18, 2017: Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks

Mar 16, 2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE

Mar 06, 2017: Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI

Mar 01, 2017: Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE

Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial

Feb 23, 2017: New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease

Jan 16, 2017: European Commission amends Marketing Authorisation for RUCONEST to include self-administration

Dec 15, 2016: CHMP Adopts Extension To Existing Therapeutic Indication For Cinryze

Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL312 in Australia

Nov 14, 2016: Pharming Announces the Presentation of the Results of the RUCONEST Phase II study for Prophylaxis of Hereditary Angioedema Attacks

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Adverum Biotechnologies Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by BioCryst Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Cevec Pharmaceuticals GmbH, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by CSL Ltd, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Global Blood Therapeutics Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by iBio Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Kalvista Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Pharming Group NV, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by ProMetic Life Sciences Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Shire Plc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Dormant Projects, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports